Synopsis
Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol
2. Metaoxedrin
3. Metasympatol
4. Mezaton
5. Neo Synephrine
6. Neo-synephrine
7. Neosynephrine
8. Phenylephrine
9. Phenylephrine Tannate
10. Tannate, Phenylephrine
1. 61-76-7
2. Phenylephrine Hcl
3. Biomydrin
4. Nostril
5. (r)-phenylephrine Hydrochloride
6. L-phenylephrine Hydrochloride
7. (r)-(-)-phenylephrine Hydrochloride
8. Phenylephrine.hcl
9. Mydfrin
10. Metaoxedrine Chloride
11. Vazculep
12. Neo-synephrine
13. Adrianol
14. Neophryn
15. Prefrin
16. Rhinall
17. Alcon Efrin
18. (-)-phenylephrine Hydrochloride
19. Nci-c55641
20. Efricel
21. Isopto Frin
22. Prefrin Liquifilm
23. (r)-3-(1-hydroxy-2-(methylamino)ethyl)phenol Hydrochloride
24. 3-[(1r)-1-hydroxy-2-(methylamino)ethyl]phenol;hydrochloride
25. Afrin 4 Hour Nasal Spray
26. Nsc-757273
27. 04ja59tnsj
28. Phenylephrine (hydrochloride)
29. Mls000069696
30. Ncgc00024257-04
31. Neosympatol
32. Synethenate
33. Almefrin
34. Consdrin
35. Emagrin
36. Fenilfar
37. Histabid
38. Idrianol
39. Lexatol
40. Oftalfrine
41. Phenistan
42. Pyristan
43. Smr000058497
44. Stanephrin
45. Sucraphen
46. Synasal
47. Fenox
48. Meta-sympatol
49. Alcon-efrin
50. (r)-(-)-1-(3-hydroxyphenyl)-2-methylaminoethanol Hydrochloride
51. [(2r)-2-hydroxy-2-(3-hydroxyphenyl)ethyl]-methylazanium;chloride
52. Dsstox_cid_1142
53. Op-isophrin
54. Dsstox_rid_75972
55. Neo-synesin 1
56. Dsstox_gsid_21142
57. Neooxedrine Chloride
58. 3-[(1r)-1-hydroxy-2-(methylamino)ethyl]phenol Hydrochloride
59. Consdrin Hydrochloride
60. Isophrin Hydrochloride
61. Vasosulf
62. Relief
63. Metaoxedrine Hydrochloride
64. Neosynephrine Hydrochloride
65. Sudafed Pe
66. Chebi:8094
67. Op-isophrin-z
68. Cas-61-76-7
69. Meta-synephrine Hydrochloride
70. Ccris 219
71. Levophenylephrine Hydrochloride
72. Phenylephrine Hydrochloride, L-
73. R-(-)-m-synephrine Hydrochloride
74. D-(-)-phenylephrine Hydrochloride
75. Einecs 200-517-3
76. Unii-04ja59tnsj
77. M-methylaminoethanolphenol Hydrochloride
78. Benzedrex Nasal Spray, Regular
79. Sr-01000075286
80. Mfcd00012605
81. Phenylephrine Hydrochloride [usp:jan]
82. Vicks Sinex Vapospray
83. Neo-synephrine (tn)
84. L-1-(m-hydroxyphenyl)-2-methyl-aminoethanol Hydrochloride
85. Vicks Sinex Nasal Spray
86. 1-m-hydroxy-alpha-(methylaminomethyl)benzyl Alcohol Hydrochloride
87. Opera_id_1786
88. (-)-m-hydroxy-alpha-((methylamino)methyl)benzyl Alcohol Hydrochloride
89. (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol Hydrochloride
90. (-)-alpha-hydroxy-beta-(methylamino)ethyl-alpha-(3-hydroxybenzene) Hydrochloride
91. Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, Hydrochloride, (-)-
92. Ec 200-517-3
93. Schembl24654
94. Mls006012005
95. Spectrum1500483
96. Phenylephrine Hydrochloride,(s)
97. Chembl1200339
98. Dtxsid3021142
99. L(-)-phenylephrine Hydrochloride
100. Hms1920h08
101. Pharmakon1600-01500483
102. Bcp23410
103. Hy-b0471
104. Tox21_110897
105. Tox21_201261
106. Tox21_302846
107. Tox21_500920
108. Ccg-39113
109. Nsc757273
110. S2569
111. Akos022190146
112. Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, Hydrochloride (r)-
113. Benzyl Alcohol, M-hydroxy-alpha-((methylamino)methyl)-, Hydrochloride, (-)-
114. Tox21_110897_1
115. Lp00920
116. Nsc 757273
117. Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, Hydrochloride, (alphar)-
118. Phenylephrine Hydrochloride (jp17/usp)
119. Phenylephrine Hydrochloride [mi]
120. Ncgc00024257-08
121. Ncgc00094231-01
122. Ncgc00256496-01
123. Ncgc00258813-01
124. Ncgc00261605-01
125. Phenylephrine Hydrochloride [jan]
126. Bp166231
127. Bcp0726000237
128. Phenylephrine Hydrochloride [mart.]
129. Phenylephrine Hydrochloride [vandf]
130. Phenylephrine Hydrochloride [usp-rs]
131. Phenylephrine Hydrochloride [who-dd]
132. (r)-(-)-phenylephrine Hydrochloride, Powder
133. Eu-0100920
134. P0398
135. Sw219446-1
136. Vu0239753-6
137. D00511
138. D70603
139. P 6126
140. Phenylephrine Hydrochloride [orange Book]
141. A833410
142. Phenylephrine Hydrochloride [ep Monograph]
143. Phenylephrine Hydrochloride [usp Monograph]
144. Omidria Component Phenylephrine Hydrochloride
145. Q-201561
146. Sr-01000075286-1
147. Phenylephrine Hydrochloride Component Of Omidria
148. Prefrin-a Component Phenylephrine Hydrochloride
149. Q27107758
150. (r)-(-)-phenylephrine Hydrochloride, Analytical Standard
151. Cyclomydril Component Phenylephrine Hydrochloride
152. Phenergan Vc Component Phenylephrine Hydrochloride
153. Phenylephrine Hydrochloride Component Of Prefrin-a
154. Pherazine Vc Component Phenylephrine Hydrochloride
155. Phenylephrine Hydrochloride Component Of Cyclomydril
156. Phenylephrine Hydrochloride Component Of Phenergan Vc
157. Phenylephrine Hydrochloride Component Of Pherazine Vc
158. Promethazine Vc Component Phenylephrine Hydrochloride
159. Phenylephrine Hydrochloride Component Of Promethazine Vc
160. (r)-(-)-phenylephrine Hydrochloride, Tested According To Ph.eur.
161. Advil Congestion Relief Component Phenylephrine Hydrochloride
162. Benzenemethanol, 3-hydroxy-a-[(methylamino)methyl]-, Hydrochloride,(ar)-
163. Phenylephrine Hydrochloride Component Of Advil Congestion Relief
164. Phenylephrine Hydrochloride, British Pharmacopoeia (bp) Reference Standard
165. Phenylephrine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
166. (-)-m-hydroxy-.alpha.-((methylamino)methyl)benzyl Alcohol Hydrochloride
167. Benzenemethanol, 3-hydroxy-.alpha.-((methylamino)methyl)-, Hydrochloride (r)-
168. Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, Hydrochloride (1:1), (alphar)-
169. Phenylephrine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
170. Phenylephrine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
171. Phenylephrine Hydrochloride For Peak Identification, European Pharmacopoeia (ep) Reference Standard
172. R-(-)-phenylephrine Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 203.66 g/mol |
|---|---|
| Molecular Formula | C9H14ClNO2 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 203.0713064 g/mol |
| Monoisotopic Mass | 203.0713064 g/mol |
| Topological Polar Surface Area | 52.5 Ų |
| Heavy Atom Count | 13 |
| Formal Charge | 0 |
| Complexity | 130 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Phenylephrine hydrochloride |
| Drug Label | NEO-SYNEPHRINE hydrochloride, brand of phenylephrine hydrochloride injectino, is a vasoconstrictor and pressor drug chemically related to epinephrine and ephedrine. NEO-SYNEPHRINE hydrochloride is a synthetic sympathomimetic agent in sterile form f... |
| Active Ingredient | Phenylephrine hydrochloride |
| Dosage Form | Solution/drops; Solution |
| Route | Ophthalmic; Iv (infusion) |
| Strength | 10mg/ml (10mg/ml); 10%; 2.5% |
| Market Status | Prescription |
| Company | West Ward Pharm; Paragon Bioteck |
| 2 of 2 | |
|---|---|
| Drug Name | Phenylephrine hydrochloride |
| Drug Label | NEO-SYNEPHRINE hydrochloride, brand of phenylephrine hydrochloride injectino, is a vasoconstrictor and pressor drug chemically related to epinephrine and ephedrine. NEO-SYNEPHRINE hydrochloride is a synthetic sympathomimetic agent in sterile form f... |
| Active Ingredient | Phenylephrine hydrochloride |
| Dosage Form | Solution/drops; Solution |
| Route | Ophthalmic; Iv (infusion) |
| Strength | 10mg/ml (10mg/ml); 10%; 2.5% |
| Market Status | Prescription |
| Company | West Ward Pharm; Paragon Bioteck |
Mydriatics
Agents that dilate the pupil. They may be either sympathomimetics or parasympatholytics. (See all compounds classified as Mydriatics.)
Nasal Decongestants
Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993) (See all compounds classified as Nasal Decongestants.)
Sympathomimetics
Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)
Vasoconstrictor Agents
Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)
Adrenergic alpha-1 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Agonists.)
Cardiotonic Agents
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.
Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.
Certificate Number : R1-CEP 2015-075 - Rev 00
Status : Valid
Issue Date : 2021-03-25
Type : Chemical
Substance Number : 632
Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.
Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.
Certificate Number : R1-CEP 2006-231 - Rev 01
Status : Valid
Issue Date : 2016-10-20
Type : Chemical
Substance Number : 632
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
Certificate Number : CEP 2018-142 - Rev 03
Status : Valid
Issue Date : 2025-02-20
Type : Chemical
Substance Number : 1035
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
Certificate Number : R1-CEP 2003-179 - Rev 04
Status : Valid
Issue Date : 2021-09-13
Type : Chemical
Substance Number : 632
Certificate Number : R1-CEP 1996-065 - Rev 05
Status : Withdrawn by Holder
Issue Date : 2014-11-18
Type : Chemical
Substance Number : 632
Certificate Number : R1-CEP 2003-167 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2009-07-20
Type : Chemical
Substance Number : 1035
Certificate Number : R1-CEP 2005-291 - Rev 06
Status : Valid
Issue Date : 2021-09-15
Type : Chemical
Substance Number : 632
Certificate Number : R1-CEP 2009-286 - Rev 00
Status : Valid
Issue Date : 2017-06-02
Type : Chemical
Substance Number : 632
Certificate Number : R0-CEP 2001-260 - Rev 01
Status : Withdrawn by Holder
Issue Date : 2005-11-22
Type : Chemical
Substance Number : 632
Certificate Number : R0-CEP 2001-333 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2005-09-21
Type : Chemical
Substance Number : 1035
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
The Company intends to use the net proceeds for the commercialization activities for Mydcombi, the first and only FDA-approved fixed dose combination ophthalmic spray for pupil dilation.
Lead Product(s): Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area: Ophthalmology Brand Name: Mydcombi
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Chardan Healthcare
Deal Size: $1.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 25, 2024
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Chardan Healthcare
Deal Size : $1.3 million
Deal Type : Public Offering
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering
Details : The Company intends to use the net proceeds for the commercialization activities for Mydcombi, the first and only FDA-approved fixed dose combination ophthalmic spray for pupil dilation.
Product Name : Mydcombi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 25, 2024
Details:
Mydcombi is FDA approved, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).
Lead Product(s): Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area: Ophthalmology Brand Name: Mydcombi
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 25, 2024
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eyenovia Provides Update on Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
Details : Mydcombi is FDA approved, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).
Product Name : Mydcombi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2024
Details:
Mydcombi is Eyenovia's investigational, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).
Lead Product(s): Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area: Ophthalmology Brand Name: Mydcombi
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 01, 2023
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From ...
Details : Mydcombi is Eyenovia's investigational, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).
Product Name : Mydcombi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 01, 2023
Details:
Mydcombi is Eyenovia's USFDA approved, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).
Lead Product(s): Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area: Ophthalmology Brand Name: Mydcombi
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 05, 2023
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Al...
Details : Mydcombi is Eyenovia's USFDA approved, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).
Product Name : Mydcombi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 05, 2023
Details:
Under the terms of the Agreement, the royalty rate applicable to U.S. net sales of OMIDRIA (phenylephrine) decreased from 50 percent to 30 percent of U.S. net sales following achievement of the Milestone Event.
Lead Product(s): Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area: Ophthalmology Brand Name: Omidria
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Rayner
Deal Size: $1,326.0 million Upfront Cash: $126.0 million
Deal Type: Divestment June 02, 2023
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Rayner
Deal Size : $1,326.0 million
Deal Type : Divestment
Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
Details : Under the terms of the Agreement, the royalty rate applicable to U.S. net sales of OMIDRIA (phenylephrine) decreased from 50 percent to 30 percent of U.S. net sales following achievement of the Milestone Event.
Product Name : Omidria
Product Type : Other Small Molecule
Upfront Cash : $126.0 million
June 02, 2023
Details:
Mydcombi is Eyenovia's investigational, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).
Lead Product(s): Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area: Ophthalmology Brand Name: Mydcombi
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 13, 2022
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dila...
Details : Mydcombi is Eyenovia's investigational, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).
Product Name : Mydcombi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2022
Details:
The financing is intended to support manufacturing in anticipation of a MydCombi (tropicamide) launch and clinical supply for ongoing programs. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis and myopia progression.
Lead Product(s): Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area: Ophthalmology Brand Name: Mydcombi
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Avenue Venture Opportunities Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing November 29, 2022
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Avenue Venture Opportunities Fund
Deal Size : Undisclosed
Deal Type : Financing
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
Details : The financing is intended to support manufacturing in anticipation of a MydCombi (tropicamide) launch and clinical supply for ongoing programs. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis and myopia...
Product Name : Mydcombi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 29, 2022
Details:
MydCombi™ has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery.
Lead Product(s): Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area: Ophthalmology Brand Name: MydCombi
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 02, 2022
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission
Details : MydCombi™ has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery.
Product Name : MydCombi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 02, 2022
Details:
Under terms of the agreement, Dr Reddy’s purchased the Biorphen® (phenylephrine hydrochloride), Rezipres®, and Cysteine Hydrochloride products. Dr Reddy’s will immediately take ownership of Eton’s rights and interests in the products.
Lead Product(s): Phenylephrine Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Biorphen
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Dr. Reddy's Laboratories
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition June 24, 2022
Lead Product(s) : Phenylephrine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Dr. Reddy's Laboratories
Deal Size : $50.0 million
Deal Type : Acquisition
Eton Pharmaceuticals Announces Sale of Hospital Products
Details : Under terms of the agreement, Dr Reddy’s purchased the Biorphen® (phenylephrine hydrochloride), Rezipres®, and Cysteine Hydrochloride products. Dr Reddy’s will immediately take ownership of Eton’s rights and interests in the products.
Product Name : Biorphen
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 24, 2022
Details:
Under the Royalty Purchase Agreement, DRI is entitled to royalties on net sales of OMIDRIA (having phenylephrine) received between September 1, 2022 and December 31, 2030, subject to annual caps.
Lead Product(s): Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area: Neurology Brand Name: Omidria
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: DRI Healthcare Trust
Deal Size: $188.4 million Upfront Cash: Undisclosed
Deal Type: Agreement March 10, 2022
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : DRI Healthcare Trust
Deal Size : $188.4 million
Deal Type : Agreement
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
Details : Under the Royalty Purchase Agreement, DRI is entitled to royalties on net sales of OMIDRIA (having phenylephrine) received between September 1, 2022 and December 31, 2030, subject to annual caps.
Product Name : Omidria
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - SOLUTION;INTRAVENOUS - 0.5MG/5ML (0....DOSAGE - SOLUTION;INTRAVENOUS - 0.5MG/5ML (0.1MG/ML)
USFDA APPLICATION NUMBER - 203826
DOSAGE - SOLUTION;INTRAVENOUS - 100MG/10ML (1...DOSAGE - SOLUTION;INTRAVENOUS - 100MG/10ML (10MG/ML)
USFDA APPLICATION NUMBER - 203826
DOSAGE - SOLUTION;INTRAVENOUS - 10MG/ML (10MG...DOSAGE - SOLUTION;INTRAVENOUS - 10MG/ML (10MG/ML)
USFDA APPLICATION NUMBER - 203826
DOSAGE - SOLUTION;INTRAVENOUS - 1MG/10ML (0.1...DOSAGE - SOLUTION;INTRAVENOUS - 1MG/10ML (0.1MG/ML)
USFDA APPLICATION NUMBER - 203826
DOSAGE - SOLUTION;INTRAVENOUS - 50MG/5ML (10M...DOSAGE - SOLUTION;INTRAVENOUS - 50MG/5ML (10MG/ML)
USFDA APPLICATION NUMBER - 203826
DOSAGE - SOLUTION;INTRAVENOUS - 100MG/10ML (1...DOSAGE - SOLUTION;INTRAVENOUS - 100MG/10ML (10MG/ML)
USFDA APPLICATION NUMBER - 204300
DOSAGE - SOLUTION;INTRAVENOUS - 10MG/ML (10MG...DOSAGE - SOLUTION;INTRAVENOUS - 10MG/ML (10MG/ML)
USFDA APPLICATION NUMBER - 204300
DOSAGE - SOLUTION;INTRAVENOUS - 50MG/5ML (10M...DOSAGE - SOLUTION;INTRAVENOUS - 50MG/5ML (10MG/ML)
USFDA APPLICATION NUMBER - 204300
DOSAGE - SOLUTION/DROPS;OPHTHALMIC - 10%
USFDA APPLICATION NUMBER - 207926
DOSAGE - SOLUTION/DROPS;OPHTHALMIC - 2.5%
USFDA APPLICATION NUMBER - 207926
DOSAGE - TABLET;ORAL - 4MG;200MG;10MG
USFDA APPLICATION NUMBER - 22113
DOSAGE - TABLET;ORAL - 200MG;10MG
USFDA APPLICATION NUMBER - 22565
DOSAGE - SOLUTION/DROPS;OPHTHALMIC - 0.2%;1%
USFDA APPLICATION NUMBER - 84300
DOSAGE - SYRUP;ORAL - 5MG/5ML;6.25MG/5ML
USFDA APPLICATION NUMBER - 88761
Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Minakem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kewpie Corporation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Minbiotech
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Capital Farma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Beneo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Bioplus Life Sciences
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CD Formulation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Esteem Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Huzhou Sunflower Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lubrizol Life Science Health
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nippon Fine Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shandong Focus Biotechnology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Welltone Material Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Symrise
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vasa Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Topical
Thickeners and Stabilizers
Coating Systems & Additives
Solubilizers
Taste Masking
Direct Compression
Disintegrants & Superdisintegrants
Parenteral
Controlled & Modified Release
Granulation
Lubricants & Glidants
Film Formers & Plasticizers
Emulsifying Agents
Co-Processed Excipients
Chewable & Orodispersible Aids
Rheology Modifiers
Surfactant & Foaming Agents
API Stability Enhancers
Empty Capsules
Application : Empty Capsules
Excipient Details : Quali-V®-I is the first plant-based capsule that responds to the particular functional properties required for use in dry powder inhaler (DPI) devices.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Application : Empty Capsules
Excipient Details : ACGCAPS™ GL / HL is available in gelatin and cellulose (HPMC) material options and can be used for liquids, semi-liquids, hot-melts and combination fills.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Gelatin, Unspecified
Application : Empty Capsules
Excipient Details : ACGCAPS™ GR can fulfill immediate release needs and is available in 15 sizes (from # 000 to # 5).
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Gelatin, Unspecified
Application : Empty Capsules
Excipient Details : Quali-G™ is first preservative-free gelatin capsule, the market standard solid dosage form designed to meet the demanding requirements of the pharmaceutical industry.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Gelatin, Unspecified
Application : Empty Capsules
Excipient Details : ACGCAPS™ GI / HI is available in gelatin and cellulose (HPMC) material options and is designed for optimal performance with DPI formulations and various inhalation devices.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Gelatin, Unspecified
Application : Empty Capsules
Excipient Details : ACGCAPS™ GC is specially designed for use in clinical trials and comes in the available sizes: AA, A & B.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Gelatin, Unspecified
Application : Empty Capsules
Excipient Details : DBcaps® capsules are developed with a tamper-evident design to specifically address the clinical trial challenges of testing without bias.
Pharmacopoeia Ref : Not Available
Technical Specs : Size # AAA- E
Ingredient(s) : Gelatin, Unspecified
Application : Empty Capsules
Pharmacopoeia Ref : Certified Vegan, Non-GMO, Vege...
Technical Specs : Size # 00el - 4
Ingredient(s) : Gelatin, Unspecified
Application : Empty Capsules
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Gelatin, Unspecified
Coloring Agents
Vegetarian Capsules
Soft Gelatin
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
67
PharmaCompass offers a list of Phenylephrine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Phenylephrine Hydrochloride manufacturer or Phenylephrine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Phenylephrine Hydrochloride manufacturer or Phenylephrine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Phenylephrine Hydrochloride API Price utilized in the formulation of products. Phenylephrine Hydrochloride API Price is not always fixed or binding as the Phenylephrine Hydrochloride Price is obtained through a variety of data sources. The Phenylephrine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A VAZCULEP manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of VAZCULEP, including repackagers and relabelers. The FDA regulates VAZCULEP manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. VAZCULEP API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of VAZCULEP manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A VAZCULEP supplier is an individual or a company that provides VAZCULEP active pharmaceutical ingredient (API) or VAZCULEP finished formulations upon request. The VAZCULEP suppliers may include VAZCULEP API manufacturers, exporters, distributors and traders.
click here to find a list of VAZCULEP suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A VAZCULEP DMF (Drug Master File) is a document detailing the whole manufacturing process of VAZCULEP active pharmaceutical ingredient (API) in detail. Different forms of VAZCULEP DMFs exist exist since differing nations have different regulations, such as VAZCULEP USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A VAZCULEP DMF submitted to regulatory agencies in the US is known as a USDMF. VAZCULEP USDMF includes data on VAZCULEP's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The VAZCULEP USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of VAZCULEP suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The VAZCULEP Drug Master File in Japan (VAZCULEP JDMF) empowers VAZCULEP API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the VAZCULEP JDMF during the approval evaluation for pharmaceutical products. At the time of VAZCULEP JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of VAZCULEP suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a VAZCULEP Drug Master File in Korea (VAZCULEP KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of VAZCULEP. The MFDS reviews the VAZCULEP KDMF as part of the drug registration process and uses the information provided in the VAZCULEP KDMF to evaluate the safety and efficacy of the drug.
After submitting a VAZCULEP KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their VAZCULEP API can apply through the Korea Drug Master File (KDMF).
click here to find a list of VAZCULEP suppliers with KDMF on PharmaCompass.
A VAZCULEP CEP of the European Pharmacopoeia monograph is often referred to as a VAZCULEP Certificate of Suitability (COS). The purpose of a VAZCULEP CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of VAZCULEP EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of VAZCULEP to their clients by showing that a VAZCULEP CEP has been issued for it. The manufacturer submits a VAZCULEP CEP (COS) as part of the market authorization procedure, and it takes on the role of a VAZCULEP CEP holder for the record. Additionally, the data presented in the VAZCULEP CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the VAZCULEP DMF.
A VAZCULEP CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. VAZCULEP CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of VAZCULEP suppliers with CEP (COS) on PharmaCompass.
A VAZCULEP written confirmation (VAZCULEP WC) is an official document issued by a regulatory agency to a VAZCULEP manufacturer, verifying that the manufacturing facility of a VAZCULEP active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting VAZCULEP APIs or VAZCULEP finished pharmaceutical products to another nation, regulatory agencies frequently require a VAZCULEP WC (written confirmation) as part of the regulatory process.
click here to find a list of VAZCULEP suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing VAZCULEP as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for VAZCULEP API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture VAZCULEP as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain VAZCULEP and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a VAZCULEP NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of VAZCULEP suppliers with NDC on PharmaCompass.
VAZCULEP Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of VAZCULEP GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right VAZCULEP GMP manufacturer or VAZCULEP GMP API supplier for your needs.
A VAZCULEP CoA (Certificate of Analysis) is a formal document that attests to VAZCULEP's compliance with VAZCULEP specifications and serves as a tool for batch-level quality control.
VAZCULEP CoA mostly includes findings from lab analyses of a specific batch. For each VAZCULEP CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
VAZCULEP may be tested according to a variety of international standards, such as European Pharmacopoeia (VAZCULEP EP), VAZCULEP JP (Japanese Pharmacopeia) and the US Pharmacopoeia (VAZCULEP USP).
